Pregabalin Capsule
Product Images NDC 71205-621

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71205-621). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

71205-621-60 (Pregabalin 75mg 90s)

This is the label of Pregabalin 75mg capsules packaged by Proficient Rx LP with lot number, expiration date, and NDC code mentioned. The capsules have white/orange color with 'A009' and 'PREG 75' imprinted on the cap and body respectively. The manufacturer is Alkem Laboratories Ltd., Mumbai - 400 013, INDIA. It is an RX-only medicine and should be stored at 25°C away from children. There is also a mention of the medication guide to be given to each patient.*

FDA Label Image

Pregabalin-equation (Pregabalin Equation)

This text appears to be a formulaic expression commonly used in medical laboratories to calculate the estimated creatinine clearance (CLCr) of a patient, which is a measure of their kidney function. The formula requires the patient's age and weight, as well as their serum creatinine level (measured in mg/dL). The value of CLCr is then determined based on these inputs, alongside a correction factor (0.85 for female patients). However, without further context or instructions for how to use the formula, this text is not particularly useful on its own.*

FDA Label Image

Pregabalin-figure-6 (Pregabalin Figure 6)

This appears to be a table of results from two different studies labeled as "Study E1" and "Study E3". The table shows the percentage results of different treatment dosages (ranging from 50mg/day to 600mg/day) compared to a placebo, for an unknown subject. The last row shows that the results were statistically significant compared to the placebo. There is not enough information to determine what the treatment was for or any other details about the studies.*

FDA Label Image

Pregabalin-figure-7 (Pregabalin Figure 7)

FDA Label Image

Study Dpn 1 (Pregabalin Image 1)

FDA Label Image

Study Sci 1 (Pregabalin Image 10)

FDA Label Image

Pain Intensity-study Sci 2 (Pregabalin Image 11)

FDA Label Image

Study Dpn 2 (Pregabalin Image 2)

FDA Label Image

Study Phn 1 (Pregabalin Image 3)

FDA Label Image

Study Phn 2 (Pregabalin Image 4)

FDA Label Image

Study Phn 3 (Pregabalin Image 5)

FDA Label Image

Fibromyalgia Study F1 (Pregabalin Image 8)

This appears to be a chart showing the percentage of patients who experienced improvement in pain from baseline with different doses of pregabalin. The chart displays percentages ranging from 0% to 100%, with the highest improvement seen in patients taking a daily dose of 600mg (labeled as "Pregabalin 450mg daiy dose" and "Pregabaiin 300mg dai dose" are other dosages), while the lowest improvement was seen in patients taking a daily dose of 100mg ("Fiacsto").*

FDA Label Image

Fibromyalgia Study F2 (Pregabalin Image 9)

FDA Label Image

Pregabalin Structure (Pregabalin Srtuc 1)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.